Metabotropic glutamate receptors for new treatments in schizophrenia.

Abstract

Metabotropic glutamate receptors (mGluRs) represent exciting targets for the development of novel therapeutic agents for schizophrenia. Recent studies indicate that selective activation of specific mGluR subtypes may provide potential benefits for not only the positive symptoms, but also the negative symptoms and cognitive impairments observed in individuals with schizophrenia. Although optimization of traditional orthosteric agonists may still offer a feasible approach for the activation of mGluRs, important progress has been made in the discovery of novel subtype-selective allosteric ligands, including positive allosteric modulators (PAMs) of mGluR2 and mGluR5. These allosteric mGluR ligands have improved properties for clinical development and have served as key preclinical tools for a more in-depth understanding of the potential roles of these different mGluR subtypes for the treatment of schizophrenia.

• Authors: E J Herman, M Bubser, P J Conn, C K Jones
• Journal: Handbook of experimental pharmacology (Handb Exp Pharmacol) Issue 213 Pg. 297-365 ( 2012) ISSN: 0171-2004 [Print] Germany
• PMID: 23027420 (Publication Type: Journal Article, Review)

Chemical References

• Ligands
• Receptors, Metabotropic Glutamate

Topics

• Allosteric Regulation
• Animals
• Cognition (drug effects)
• Humans
• Ligands
• Receptors, Metabotropic Glutamate (analysis, chemistry, drug effects, physiology)
• Schizophrenia (drug therapy)
• Signal Transduction